\-\ Texto\\:\\ \ \(0\)\
\-\ csf\\ positive\\ for\\ ms\ \(0\)\
\-\ steroids\\ only\\.\ \(0\)\
\-\ \\â\\€\\¢\\ mr\\:\\ lesion\\ left\\ middle\\ cerebral\\ peduncle\\ which\\ has\\ low\\ signal\\ on\\ t1\\ and\\ elevated\\ signal\\ on\\ t2\\ mr\ \(0\)\
\-\ \\â\\€\\¢\\ me\\+gd\\:\\ lesion\\ left\\ middle\\ cerebellar\\ peduncle\\ enhances\\.\ \(0\)\
\-\ acute\\ multiple\\ sclerosis\\ \\-\\ enhancing\\ lesion\\ with\\ mass\\ effect\\.\ \(0\)\
\-\ metastatic\\ disease\ \(243\)\
\-\ lymphoma\ \(373\)\
\-\ infarction\ \(233\)\
\-\ 65\\ year\\ old\\ man\\ with\\ history\\ of\\ left\\ thalamic\\ infarct\\.\ \(1\)\
\-\ now\\ presents\\ with\\ new\\ onset\\ of\\ left\\ sided\\ facial\\ pain\\ and\\ numbness\ \(0\)\
\-\ repeat\\ mri\\ 2\\ weeks\\ after\\ steroid\\ treatment\\ revealed\\ almost\\ complete\\ resolution\\ of\\ the\\ lesion\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ peduncle\\:\\ 0\\.38113173654130567\ \(0\)\
\-\ lesion\\:\\ 0\\.2875077312808004\ \(0\)\
\-\ middle\\:\\ 0\\.21441635089788838\ \(0\)\
\-\ left\\:\\ 0\\.20456947623523572\ \(0\)\
\-\ mr\\:\\ 0\\.1940154104850876\ \(0\)\
\-\ thalamic\\:\\ 0\\.17924388243829067\ \(0\)\
\-\ signal\\:\\ 0\\.1699753819790508\ \(0\)\
\-\ ms\\:\\ 0\\.1455779353713413\ \(0\)\
\-\ steroid\\:\\ 0\\.1445050375698233\ \(0\)\
\-\ almost\\:\\ 0\\.1346791256167086\ \(0\)\
\-\ numbness\\:\\ 0\\.13327080589718207\ \(0\)\
\-\ enhances\\:\\ 0\\.13215223936754517\ \(0\)\
\-\ steroids\\:\\ 0\\.13171781052759024\ \(0\)\
\-\ repeat\\:\\ 0\\.13150325956944148\ \(0\)\
\-\ 65\\:\\ 0\\.12828920252329906\ \(0\)\
\-\ infarct\\:\\ 0\\.1247560596218156\ \(0\)\
\-\ facial\\:\\ 0\\.1236237218859849\ \(0\)\
\-\ cerebellar\\:\\ 0\\.12269052279974967\ \(0\)\
\-\ resolution\\:\\ 0\\.1216420850711182\ \(0\)\
\-\ csf\\:\\ 0\\.11846502532127702\ \(0\)\
\-\ infarction\\:\\ 0\\.11769573099383301\ \(0\)\
\-\ sclerosis\\:\\ 0\\.1067876489348461\ \(0\)\
\-\ effect\\:\\ 0\\.10516976306617794\ \(0\)\
\-\ complete\\:\\ 0\\.10509142516490357\ \(0\)\
\-\ cerebral\\:\\ 0\\.10386876999854483\ \(0\)\
\-\ new\\:\\ 0\\.10371986112190995\ \(0\)\
\-\ now\\:\\ 0\\.10291560974544622\ \(0\)\
\-\ elevated\\:\\ 0\\.10220523281448664\ \(0\)\
\-\ positive\\:\\ 0\\.09879226020802186\ \(0\)\
\-\ revealed\\:\\ 0\\.09830440682437805\ \(0\)\
\-\ sided\\:\\ 0\\.0964388010734201\ \(0\)\
\-\ onset\\:\\ 0\\.09627050372298507\ \(0\)\
\-\ enhancing\\:\\ 0\\.09391848154122319\ \(0\)\
\-\ only\\:\\ 0\\.09366405219299481\ \(0\)\
\-\ t1\\:\\ 0\\.09341206228163339\ \(0\)\
\-\ on\\:\\ 0\\.09055928320906251\ \(0\)\
\-\ weeks\\:\\ 0\\.08985243461220847\ \(0\)\
\-\ lymphoma\\:\\ 0\\.08928906513872362\ \(0\)\
\-\ with\\:\\ 0\\.08807101987171279\ \(0\)\
\-\ of\\:\\ 0\\.08801842888142977\ \(0\)\
\-\ t2\\:\\ 0\\.08625545416133978\ \(0\)\
\-\ low\\:\\ 0\\.08602724132586075\ \(0\)\
\-\ metastatic\\:\\ 0\\.08222585085499179\ \(0\)\
\-\ acute\\:\\ 0\\.08110318826886415\ \(0\)\
\-\ man\\:\\ 0\\.07937166248364831\ \(0\)\
\-\ mri\\:\\ 0\\.076957713160744\ \(0\)\
\-\ multiple\\:\\ 0\\.07333112406294609\ \(0\)\
\-\ after\\:\\ 0\\.07273062253922088\ \(0\)\
\-\ presents\\:\\ 0\\.07212121494262742\ \(0\)\
\-\ treatment\\:\\ 0\\.07141678828256025\ \(0\)\
\-\ has\\:\\ 0\\.0684809453319738\ \(0\)\
\-\ which\\:\\ 0\\.06817196488675102\ \(0\)\
\-\ disease\\:\\ 0\\.06293279718457644\ \(0\)\
\-\ and\\:\\ 0\\.0619599458161536\ \(0\)\
\-\ history\\:\\ 0\\.05727967276300597\ \(0\)\
\-\ mass\\:\\ 0\\.05726699129283493\ \(0\)\
\-\ pain\\:\\ 0\\.053648348533870203\ \(0\)\
\-\ year\\:\\ 0\\.046203645661165665\ \(0\)\
\-\ for\\:\\ 0\\.04544083405349602\ \(0\)\
\-\ old\\:\\ 0\\.04437149362357571\ \(0\)\
\-\ the\\:\\ 0\\.029915283792456285\ \(0\)\
